Synergy between human immunodeficiency virus type 1 and Epstein-Barr virus in T lymphoblastoid cell lines

AIDS Research and Human Retroviruses

Volumn 13, Issue 2, 1997, Pages 161-172

  Zhang, Ren De ^a,b   Guan, Mingxu ^a   Park, Young ^a,c   Tawadros, Rick ^a   Yang, Jyh Yuan ^a,d   Gold, Bert ^a,e   Wu, Brian ^f   Henderson, Earl E ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Shin Chonyoun Hap Hospital   (South Korea)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS ISOLATION; VIRUS REPLICATION;

EID: 0031021401     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.161     Document Type: Article

References (59)

1. Bower M: The biology of HIV-associated lymphomas. Br J Cancer 1992;66:421-423.
2. Haluska FG, Russo G, Kant J, Andreef M, and Croce CM: Molecular resemblance of an AIDS-associated lymphoma and endemic Burkitt lymphomas: Implications for their pathogenesis. Proc Natl Acad Sci USA 1989;86:8907-8911.
3. JeVon GP, Elavathil LJ, Harnish DG, and deSa DJ: Epstein-Barr virus in non-Hodgkin's lymphomas and lymphoid tissue in children. Pediatr Pathol Lab Med 1995;15:283-290.
4. McClain KL, Leach CT, Jenson HB, Joshi VV, Pollock BH, Parmley RT, DiCarlo FJ, Chadwick EG, and Murphy SB: Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N Engl J Med 1995;332:12-18.
5. De Rossi A, Roncella S, Calabro ML, D'Andrea E, Pasti M, Panozzo M, Mammano F, Ferrarini M, and Chieco-Bianchi L: Infection of Epstein-Barr virus-transformed lymphoblastoid B cells by the human immunodeficiency virus: Evidence for a persistent and productive infection leading to B cell phenotypic changes. Eur J Immunol 1990;20:2041-2049.
6. Rahman MA, Kingsley LA, Atchison RW, Belle S, Breinig MC, Ho M, and Rinaldo CR Jr: Reactivation of Epstein-Barr virus during early infection with human immunodeficiency virus. J Clin Microbiol 1991;29:1215-1220.
7. Tozzi V, Britton S, Ehrnst A, Lenkei R, and Strannegard O: Persistent productive HIV infection in EBV-transformed B lymphocytes. J Med Virol 1989;27:19-24.
8. Dahl KE, Burrage T, Jones F, and Miller G: Persistent nonproductive infection of Epstein-Barr virus-transformed human B lymphocytes by human immunodeficiency virus type 1. J Virol 1990;64:1771-1783.
9. Henderson EE, Yang JY, Zhang RD, and Bealer M: Altered HIV expression and EBV-induced transformation in coinfected PBLs and PBL subpopulations. Virology 1991;182:186-198.
10. Monroe JE, Calender A, and Mulder C: Epstein-Barr virus-positive and -negative B-cell lines can be infected with human immunodeficiency virus types 1 and 2. J Virol 1988;62:3497-3500.
11. Zhang RD and Henderson EE: CD4 mRNA expression in CD19-positive B cells and its suppression by the Epstein-Barr virus. Virology 1994;198:709-713.
12. Molina H, Brenner C, Jacobi S, Gorka J, Carel J-C, Kinoshita T, and Holers VM: Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. J Biol Chem 1991;266:12173-12179.
13. Birkenback M, Tong X, Bradbury LE, Teddler TF, and Kieff E: Characterization of an Epstein-Barr virus receptor on human epithelial cells. J Exp Med 1992;176:1405-1414.
14. Li QX, Young LS, Niedobitek G, Dawson CW, Birkenbach M, Wang F, and Rickinson AB: Epstein-Barr virus infection and replication in a human epithelial cell system. Nature (London) 1992;356:347.
15. Young LS, Dawson CW, Brown KW, and Rickinson AB: Identification of a human epithelial cell surface protein sharing an epitope with the CD3/Epstein-Barr virus receptor molecule of B lymphocytes. Int J Cancer 1989;43:786-794.
16. Koizumi S, Zhang XK, Imai S, Sugiura M, Usui N, and Osato T: Infection of the HTLV-1-harbouring T-lymphoblastoid line MT-2 by Epstein-Barr virus. Virology 1992;188:859-863.
17. Watry D, Hedrick JA, Siervo S, Rhodes G, Lamberti JJ, Lambris JD, and Tsoukas CD: Infection of human thymocytes by Epstein-Barr virus. J Exp Med 1991;173:971-980.
18. Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, and Osato T: Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 1990;335:128-130.
19. Chang Y-S, Su I-J, Chung P-J, Shu C-H, Ng C-K, Wu SJ, and Liu S-T: Detection of an Epstein-Barr-virus variant in T-cell-lymphoma tissues identical to the distinct strain observed in nasopharyngeal carcinoma in the Taiwanese population. Int J Cancer 1995;62:673-677.
20. Ishihara S, Tawa A, Yumura-Yagi K, Murata M, Hara JI, Yabuuchi H, Kiral K, and Kawa-Ha K: Clonal T-cell lymphoproliferation containing Epstein-Barr (EB) virus DNA in a patient with chronic active EB virus infection. Jpn J Cancer Res 1989;80:99-101.
21. Fischer E, Delibrias C, and Kazatchkine MD: Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol 1991;146:865-869.
22. Tsoukas CD and Lambris JD: Expression of EBV/C3d receptors on T cells: Biological significance. Immunol Today 1993; 14:56-59.
23. Sinha SK, Todd SC, Hedrick JA, Speiser CL, Lambris JD, and Tsoukas CD: Characterization of the EBV/C3d receptor on the human Jurkat T cell line: Evidence for a novel transcript. J Immunol 1993;150:5311-5320.
24. Fujiwara S and Ono Y: Isolation of Epstein-Barr virus-infected clones of the human T cell line MT-2: Use of recombinant viruses with a positive selection marker. J Virol 1995;69:3900-3903.
25. Hammarskjöld M-L and Simurda MC: Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J Virol 1992;66:6496-6501.
26. Scala G, Quinto I, Ruocco MR, Mallardo M, Ambrosino C, Squitieri B, Tassone P, and Venuta S: Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1. J Virol 1993;67:2853-2861.
27. Henderson EE, Heston L, Grogan E, and Miller G: Radiobiologic inactivation of Epstein-Barr virus. J Virol 1978;25:51-59.
28. Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, and Kieff E: Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 1990; 64:4084-4092.
29. Polack A, Hartl G, Zimber U, Freese UK, Laux G, Takaki K, Hohn B, Gissmann L, and Bornkamm GW: A complete set of overlapping cosmid clones of M-ABA virus derived from nasopharyngeal carcinoma and its similarity to other Epstein-Barr virus isolates. Gene 1984;27:279-288.
30. Gorman CM, Moffat LF, and Howard BH: Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 1982;2:1044-1051.
31. Bacheler LT, Strehl LL, Neubauer RH, Petteway SR Jr, and Ferguson BQ: Stable indicator cell lines exhibiting HIV-1 tat function. AIDS Res Hum Retroviruses 1989;5:275-278.
32. Mulligan RC and Berg P: Factors governing the expression of a bacterial gene in mammalian cells. Mol Cell Biol 1981;1:449-459.
33. Seed B and Sheen J-Y: A simple phase-extraction assay for chloramphenicol acetyltransferase activity. Gene 1988;67:271-277.
34. Elangovan B, Subramanian T, and Chinnadurai G: Functional comparison of the basic domains of the TAT proteins of human immunodeficiency virus types 1 and 2 in transactivation. J Virol 1992;66:2031-2036.
35. Moore MD, Cooper NR, Tack BF, and Nemerow GR: Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc Natl Acad Sci USA 1987;84:9194-9198.
36. Ponte P, Ng SY, Engel J, Gunning P, and Kedes L: evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res 1984;12:1687-1696.
37. Brooks L, Yao QY, Rickinson AB, and Young LS: Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: Coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992;66:2689-2697.
38. Tierney RJ, Steven N, Young LS, and Rickinson AB: Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994;68:7374-7385.
39. Raab-Traub N and Flynn K: The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986;47:883-889.
40. Hurley EA and Thorley-Lawson DA: B cell activation and the establishment of Epstein-Barr virus latency. J Exp Med 1988; 168:2059-2075.
41. Walls EV, Doyle MG, Patel KK, Allday MJ, Catovsky D, and Crawford DH: Activation and immortalization of leukemic B cells by Epstein-Barr virus. Int J Cancer 1989;44:846-853.
42. Laux G, Perricaudet M, Farrel PJ: A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J 1988;3:769-774.
43. Ring CJA: The B cell-immortalizing functions of Epstein-Barr virus. J Gen Virol 1994;75:1-13.
44. Todd SC and Tsoukas CD: EBV induces proliferation of immature human thymocytes in and IL-2-mediated response. J Immunol 1996;156:4217-4223.
45. Mannick JB, Cohen JI, Birkenbach M, Marchini A, and Kieff E: The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol 1991;65:6826-6837.
46. Chen C-L, Sadler RH, Walling DM, Su I-J, Hsieh H-C, and Raab-Traub N: Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol 1993;67:6303-6308.
47. Cullen BR: Regulation of HIV-1 gene expression. FASEB J 1991;5:2361-2368.
48. Libermann TA and Baltimore D: Activation of interleukin-6 gene expression through the NF-κB transcription factor. Mol Cell Biol 1990;10:2327-2334.
49. Mallon R, Borkowski J, Albin R, Pepitoni S, Schwartz J, and Kieff E: The Epstein-Barr virus BZLF-1 gene product activates the human immunodeficiency virus type 1 5′ long terminal repeat. J Virol 1990;64:6282-6285.
50. Quinlivan EB, Holley-Guthrie E, Mar E-C, Smith MS, and Kenney S: The Epstein-Barr virus BRLF1 immediate-early gene product transactivates the human immunodeficiency virus type 1 long terminal repeat by a mechanism which is enhancer independent. J Virol 1990;64:1817-1820.
51. Kenney S, Kamine J, Markovitz D, Fenrick R, and Pagano J: An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci USA 1988;85:1652-1656.
52. Grasser FA, Haiss P, Gottel S, and Mueller-Lantzsch N: Biochemical characterization of Epstein-Barr virus nuclear antigen 2A. J Virol 1991;65:3779-3788.
53. Hsieh J-D and Hayward SD: Masking of the CBF1/RBPJk transcriptional repression domain by Epstein-Barr virus EBNA2. Science 1995;268:560-563.
54. Waltzer L, Logeat F, Brou C, Israel A, Segeant A, and Manet E: The human JK recombination signal sequence binding protein (RBP-Jk) targets the Epstein-Barr virus EBNA-2 protein to its DNA responsive element. EMBO J 1994;13:5633-5638.
55. Grossman SR, Johannsen E, Tong X, Yalamanchili R, and Kieff E: The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the JK recombination signal binding protein. Proc Natl Acad Sci USA 1994;91:7598-7572.
56. Cohen JI, Wang F, and Kieff E: Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol 1991;65:2545-2554.
57. Rooney CM, Brimmell M, Buschle M, Allan G, Farrell PJ, and Kolman JL: Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes. J Virol 1992;66:496-504.
58. Cordier-Bussat M, Billaud M, Calender A, and Lenoir GM: Epstein-Barr virus (EBV) nuclear-antigen-2-induced up-regulation of CD21 and CD23 molecules is dependent on a permissive cellular context. Int J Cancer 1993;53:153-160.
59. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, and Rickinson AB: Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 1987;6:2743-2751.